Please assess the completion status of the following clinical trial:

Trial Title: Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All male patients \>=60 years old who undergo inpatient thoracic surgery for major resections.~Exclusion Criteria:~* - Prisoners~* Adults unable to consent~* End stage renal disease on hemodialysis~* Indwelling urinary catheter~* Child-Pugh class C hepatic failure~* Usage of the following medications prior to surgery: strong CYP 3A4 inhibitors, strong CYP2D6 inhibitors, other alpha-adrenergic blocking agents, PDE5 inhibitors, and cimetidine~* patients known to be CYP2D6 poor metabolizers~* History of prostatectomy or cystectomy~* Patients with contraindications to tamsulosin and those at high risk for side effects: hypersensitivity to tamsulosin HCl or any component of FLOMAX capsules, hypersensitivity to sulfonamides. History of known glaucoma, hypotension, plan to undergo cataract surgery in the next 2 weeks

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perioperative Tamsulosin Hydrochloride (Type: EXPERIMENTAL): Participants undergoing thoracic surgery will receive 0.4mgTamsulosin Hydrochloride orally nightly for the two nights immediately prior to surgery and the morning of surgery.
- Historical Comparator (Type: NO_INTERVENTION): Participants who underwent thoracic surgery (historical). Information about occurrence of Peri-Operative Urinary Retention in thoracic surgery patients will be obtained via retrospective chart review.

Based on this trial design, predict the completion outcome and termination type (if applicable).